Malcolm A Smith

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2337458/publications.pdf

Version: 2024-02-01

158 papers	20,034 citations	19636 61 h-index	11303 136 g-index
166 all docs	166 docs citations	166 times ranked	21280 citing authors

#	Article	IF	Citations
1	Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies. Laboratory Investigation, 2022, 102, 185-193.	1.7	8
2	Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Molecular Cancer Therapeutics, 2022, 21, 903-913.	1.9	12
3	Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. Neuro-Oncology, 2022, 24, 1978-1988.	0.6	14
4	Evaluation of the DLL3-targeting Antibodyâ€“Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma. Cancer Research Communications, 2022, 2, 616-623.	0.7	1
5	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 4107-4118.	0.8	11
6	In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical modelsâ€”A report from the Pediatric Preclinical Testing Consortium. Pediatric Blood and Cancer, 2021, 68, e28772.	0.8	9
7	ABBV-085, Antibodyâ€“Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Molecular Cancer Therapeutics, 2021, 20, 535-540.	1.9	17
8	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research, 2021, 27, 2179-2189.	3.2	95
9	The B7-H3â€“Targeting Antibodyâ€“Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. Clinical Cancer Research, 2021, 27, 2938-2946.	3.2	55
10	Bromodomain and extra-terminalÂinhibitorsâ€”A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in childrenâ€”ACCELERATE. European Journal of Cancer, 2021, 146, 115-124.	1.3	10
11	International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer. Molecular Cancer Therapeutics, 2021, 20, 1462-1468.	1.9	14
12	In vivo evaluation of the lysineâ€specific demethylase (KDM1A/LSD1) inhibitor SPâ€2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC). Pediatric Blood and Cancer, 2021, 68, e29304.	0.8	14
13	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. European Journal of Cancer, 2021, 157, 198-213.	1.3	34
14	Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. Leukemia, 2020, 34, 1524-1539.	3.3	20
15	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. European Journal of Cancer, 2020, 139, 135-148.	1.3	20
16	Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity. ESMO Open, 2020, 5, e000871.	2.0	2
17	ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcomaâ€”A Children's Oncology Group study. Cancer, 2020, 126, 5303-5310.	2.0	17
18	Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma. Genome Research, 2020, 30, 1228-1242.	2.4	20

#	Article	IF	Citations
19	Selumetinib in Children with Inoperable Plexiform Neurofibromas. New England Journal of Medicine, 2020, 382, 1430-1442.	13.9	360
20	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer, 2020, 127, 52-66.	1.3	52
21	Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. Clinical Cancer Research, 2020, 26, 3012-3023.	3.2	11
22	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nature Reviews Cancer, 2019, 19, 420-438.	12.8	98
23	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 2019, 29, 1675-1689.e9.	2.9	103
24	Preclinical activity of the antibodyâ€drug conjugate denintuzumab mafodotin (SGNâ€CD19A) against pediatric acute lymphoblastic leukemia xenografts. Pediatric Blood and Cancer, 2019, 66, e27765.	0.8	19
25	OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clinical Cancer Research, 2019, 25, 4493-4503.	3.2	30
26	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clinical Cancer Research, 2019, 25, 3229-3238.	3.2	61
27	Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia, 2019, 33, 1934-1943.	3.3	69
28	A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell, 2019, 36, 660-673.e11.	7.7	231
29	Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. Clinical Cancer Research, 2019, 25, 2278-2289.	3.2	57
30	Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts. , 2019, , .		1
31	Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature, 2018, 555, 371-376.	13.7	649
32	Initial testing (stage 1) of M6620 (formerly VXâ€970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2018, 65, e26825.	0.8	21
33	The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nature Medicine, 2018, 24, 103-112.	15.2	525
34	Will my child do better if she enrolls in a clinical trial?. Cancer, 2018, 124, 3965-3968.	2.0	3
35	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	13.7	236
36	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Childrenâ€™s Oncology Group Study ANBL0931. Frontiers in Immunology, 2018, 9, 1355.	2.2	66

#	Article	IF	Citations
37	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. Clinical Cancer Research, 2017, 23, 3744-3755.	3.2	16
38	A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nature Genetics, 2017, 49, 1487-1494.	9.4	255
39	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nature Genetics, 2017, 49, 1211-1218.	9.4	693
40	Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2017, 64, e26304.	0.8	20
41	Initial testing (stage 1) of tazemetostat (EPZâ€6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2017, 64, e26218.	0.8	86
42	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2017, 64, e26263.	0.8	15
43	MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2017, 35, 3964-3977.	0.8	49
44	Initial Testing (Stage 1) of MKâ€8242â€"A Novel MDM2 Inhibitorâ€"by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 1744-1752.	0.8	27
45	Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clinical Cancer Research, 2016, 22, 4105-4118.	3.2	56
46	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genetics, 2016, 209, 182-194.	0.2	38
47	CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML. Blood, 2016, 127, 3094-3098.	0.6	49
48	Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2016, 22, 5582-5591.	3.2	82
49	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Research, 2016, 76, 5798-5809.	0.4	52
50	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood, 2016, 128, 1382-1395.	0.6	148
51	A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia, 2016, 30, 2133-2141.	3.3	47
52	Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPTâ€330): A report from the pediatric preclinical testing program. Pediatric Blood and Cancer, 2016, 63, 276-286.	0.8	28
53	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. Cancer Research, 2016, 76, 4579-4591.	0.4	20
54	Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 443-450.	0.8	0

#	Article	IF	Citations
55	Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemotherapy and Pharmacology, 2016, 77, 405-412.	1.1	24
56	MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Letters, 2016, 371, 214-224.	3.2	46
57	Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Research, 2016, 76, 2197-2205.	0.4	133
58	Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia. Cancer Research, 2016, 76, 2766-2777.	0.4	16
59	Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL. JCI Insight, 2016, 1, .	2.3	41
60	AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood, 2015, 126, 1193-1202.	0.6	50
61	Initial testing (stage 1) of the antiâ€microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2015, 62, 1897-1905.	0.8	14
62	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatric Blood and Cancer, 2015, 62, 91-98.	0.8	65
63	Initial testing (stage 1) of the tubulin binding agent nanoparticle albuminâ€bound (nab) paclitaxel (Abraxane^{Â®}) by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 2015, 62, 1214-1221.	0.8	29
64	Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2015, 62, 1106-1109.	0.8	9
65	MLLT1 YEATS domain mutations in clinically distinctive Favourable Histology Wilms tumours. Nature Communications, 2015, 6, 10013.	5.8	64
66	Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors. Cancer Cell, 2015, 27, 286-297.	7.7	244
67	Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2015, 14, 364-374.	1.9	49
68	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research, 2015, 21, 819-832.	3.2	100
69	Effective Targeting of the P53â€“MDM2 Axis in Preclinical Models of Infant MLL-Rearranged Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2015, 21, 1395-1405.	3.2	43
70	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	9.4	451
71	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nature Communications, 2015, 6, 6604.	5.8	281
72	Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor. Molecular Cancer Research, 2015, 13, 1615-1626.	1.5	27

#	Article	IF	Citations
73	Efficacy of CPXâ€351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2015, 62, 65-71.	0.8	20
74	Remaining Challenges in Childhood Cancer and Newer Targeted Therapeutics. Pediatric Clinics of North America, 2015, 62, 301-312.	0.9	27
75	Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative. Blood, 2015, 126, 687-687.	0.6	2
76	Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. Blood, 2015, 126, 87-87.	0.6	19
77	TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney. Oncotarget, 2015, 6, 15828-15841.	0.8	46
78	Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer. Pediatric Blood and Cancer, 2014, 61, 1497-1505.	0.8	9
79	Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 922-924.	0.8	6
80	Initial testing (Stage 1) of TAK-701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 380-382.	0.8	5
81	Initial solid tumor testing (Stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1972-1979.	0.8	7
82	Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1486-1489.	0.8	19
83	Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2014, 61, 245-252.	0.8	37
84	Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. Clinical Cancer Research, 2014, 20, 4520-4531.	3.2	67
85	Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistanceâ€"Letter. Molecular Cancer Therapeutics, 2014, 13, 763-763.	1.9	1
86	Initial testing (stage 1) of the notch inhibitor PFâ€03084014, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1493-1496.	0.8	6
87	Initial testing (stage 1) of the poloâ€like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2014, 61, 158-164.	0.8	46
88	Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma. Clinical Cancer Research, 2014, 20, 4200-4209.	3.2	127
89	Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1816-1821.	0.8	35
90	Declining childhood and adolescent cancer mortality. Cancer, 2014, 120, 2497-2506.	2.0	410

#	Article	IF	Citations
91	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2014, 371, 1005-1015.	13.9	1,161
92	Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 633-641.	0.8	55
93	Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 783-790.	0.8	13
94	New policies to address the global burden of childhood cancers. Lancet Oncology, The, 2013, 14, e125-e135.	5.1	96
95	Initial testing (stage 1) of the phosphatidylinositol 3â€² kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 791-798.	0.8	19
96	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. Blood, 2013, 121, 485-488.	0.6	156
97	Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 1325-1332.	0.8	77
98	The genetic landscape of high-risk neuroblastoma. Nature Genetics, 2013, 45, 279-284.	9.4	990
99	The Anti-CD19 Antibodyâ€“Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2013, 19, 1795-1805.	3.2	66
100	A Proposal Regarding Reporting of In Vitro Testing Results. Clinical Cancer Research, 2013, 19, 2828-2833.	3.2	59
101	Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 1860-1867.	0.8	27
102	Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, E42-5.	0.8	11
103	Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (â€œPh-likeâ€•or â€œBCR-ABL1-Likeâ€) Signature For Therapeutic Targeting and Clinical Intervention. Blood, 2013, 122, 826-826.	0.6	65
104	A phase I clinical trial of veliparib and temozolomide in children with recurrent central nervous system tumors: A Pediatric Brain Tumor Consortium report.. Journal of Clinical Oncology, 2013, 31, 2036-2036.	0.8	2
105	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. Cancer Cell, 2012, 22, 153-166.	7.7	621
106	Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Opinion on Biological Therapy, 2012, 12, 1407-1414.	1.4	24
107	Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 191-199.	0.8	35
108	Testing of the topoisomerase 1 inhibitor Genzâ€644282 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 200-209.	0.8	16

#	Article	IF	Citations
109	Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 185-188.	0.8	14
110	Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 566-571.	0.8	26
111	Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 636-639.	0.8	73
112	Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a Î³â€secretase inhibitor targeting notch signaling. Pediatric Blood and Cancer, 2012, 58, 815-818.	0.8	31
113	Initial testing of JNJâ€26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 329-332.	0.8	22
114	Testing of the Akt/PKB inhibitor MKâ€2206 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 518-524.	0.8	36
115	Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 586-588.	0.8	33
116	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 2011, 118, 3080-3087.	0.6	255
117	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 1291-1304.	1.1	88
118	National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing. Pediatric Blood and Cancer, 2011, 56, 239-249.	0.8	77
119	Initial testing of the hypoxiaâ€activated prodrug PRâ€104 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2011, 57, 443-453.	0.8	31
120	Abstract 4756: Exome sequencing of 81 neuroblastomas identifies a wide diversity of somatic mutation. Cancer Research, 2011, 71, 4756-4756.	0.4	2
121	Abstract 926: Whole genome and transcriptome sequencing defines the spectrum of somatic changes in high-risk neuroblastoma. Cancer Research, 2011, 71, 926-926.	0.4	3
122	Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood, 2010, 116, 4874-4884.	0.6	370
123	Initial testing of topotecan by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 54, 707-715.	0.8	37
124	Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 1224-1226.	0.8	9
125	Initial testing of a monoclonal antibody (IMCâ€A12) against IGFâ€1R by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 54, 921-926.	0.8	89
126	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 2010, 55, 26-34.	0.8	195

#	Article	IF	Citations
127	Initial testing (stage 1) of AZD6244 (ARRYâ€142886) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 668-677.	0.8	94
128	Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 1329-1337.	0.8	43
129	Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 1126-1133.	0.8	51
130	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics, 2010, 9, 101-112.	1.9	89
131	Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century. Journal of Clinical Oncology, 2010, 28, 2625-2634.	0.8	850
132	Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood, 2010, 115, 1394-1405.	0.6	192
133	Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. New England Journal of Medicine, 2010, 363, 1324-1334.	13.9	1,460
134	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood, 2010, 115, 5312-5321.	0.6	503
135	JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9414-9418.	3.3	516
136	Initial testing of aplidin by the pediatric preâ€clinical testing program. Pediatric Blood and Cancer, 2009, 53, 509-512.	0.8	10
137	Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2009, 53, 505-508.	0.8	54
138	Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2009, 53, 594-598.	0.8	28
139	Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2009, 360, 470-480.	13.9	1,260
140	Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 37-45.	0.8	112
141	Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 581-587.	0.8	116
142	Initial testing of cisplatin by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 992-1000.	0.8	30
143	Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 799-805.	0.8	162
144	Initial testing of dasatinib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 1198-1206.	0.8	69

#	Article	IF	Citations
145	Initial testing (stage 1) of the BH3 mimetic ABTâ€263 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 1181-1189.	0.8	108
146	Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGFâ€1 receptor by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 50, 1190-1197.	0.8	168
147	Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17â€DMAG,) Tj ETQq1 1 0.784314 rgBT /Over	0.8	31
148	Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 51, 42-48.	0.8	88
149	Initial testing of VNP40101M (CloretazineÂ®) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2008, 51, 439-441.	0.8	7
150	Molecular Characterization of the Pediatric Preclinical Testing Panel. Clinical Cancer Research, 2008, 14, 4572-4583.	3.2	116
151	Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis. Cancer Research, 2007, 67, 32-40.	0.4	105
152	The pediatric preclinical testing program: Description of models and early testing results. Pediatric Blood and Cancer, 2007, 49, 928-940.	0.8	430
153	Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials. Journal of Clinical Oncology, 2005, 23, 7199-7206.	0.8	352
154	Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins. Journal of Clinical Oncology, 1999, 17, 569-569.	0.8	282
155	Trends in Reported Incidence of Primary Malignant Brain Tumors in Children in the United States. Journal of the National Cancer Institute, 1998, 90, 1269-1277.	3.0	269
156	Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on intergroup rhabdomyosarcoma study III: An interim report. Medical and Pediatric Oncology, 1994, 23, 99-106.	1.0	65
157	Workgroup #4: Clinical research implications. Cancer, 1993, 71, 2423-2423.	2.0	5
158	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. SSRN Electronic Journal, 0, , .	0.4	0